The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026Clinical Trial Application (CTA) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback